[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maze Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100579925","phase-2-a-phase-2-study-of-mze829-in-adults-with-apol1-kidney-disease-100579925",false,"NCT06830629","A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease","An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype","Key Inclusion Criteria:\n\n* APOL1 high risk genotype of G1\u002FG1, G2\u002FG2, or G1\u002FG2\n* Chronic kidney disease with persistent albuminuria\n\nKey Exclusion Criteria:\n\n* Organ or bone marrow transplantation\n* History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer\n* Conditions that may alter drug absorption, e.g., history of bariatric surgery\n* Type I diabetes\n* Pregnant or currently nursing\n\nOther inclusion\u002Fexclusion criteria defined in protocol apply.","ALL","18 Years","68 Years",{"count":20,"type":21},56,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease",[27],"Proteinuric Kidney Disease",[29,30],"APOL1-mediated kidney disease (AMKD)","APOL1 kidney disease (AKD)","RECRUITING","2026-04-16",{"date":34,"type":35},"2026-04-17","ACTUAL",{"date":37,"type":35},"2025-02-05",{"date":39,"type":21},"2026-09",{"name":41,"class":42},"Maze Therapeutics","INDUSTRY",81,""]